These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 9250408)

  • 1. Oxidation of low-density lipoproteins produces levuglandin-protein adducts.
    Salomon RG; Subbanagounder G; Singh U; O'Neil J; Hoff HF
    Chem Res Toxicol; 1997 Jul; 10(7):750-9. PubMed ID: 9250408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Paal-Knorr agent for chemoproteomic profiling of targets of isoketals in cells.
    Wang MR; He JY; He JX; Liu KK; Yang J
    Chem Sci; 2021 Nov; 12(43):14557-14563. PubMed ID: 34881007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycolaldehyde is an endogenous source of lysine
    Chikazawa M; Yoshitake J; Lim SY; Iwata S; Negishi L; Shibata T; Uchida K
    J Biol Chem; 2020 May; 295(22):7697-7709. PubMed ID: 32332094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions.
    Davies SS; May-Zhang LS; Boutaud O; Amarnath V; Kirabo A; Harrison DG
    Pharmacol Ther; 2020 Jan; 205():107418. PubMed ID: 31629006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactive Carbonyl Species Scavengers-Novel Therapeutic Approaches for Chronic Diseases.
    Davies SS; Zhang LS
    Curr Pharmacol Rep; 2017 Apr; 3(2):51-67. PubMed ID: 28993795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total Synthesis Confirms the Molecular Structure Proposed for Oxidized Levuglandin D
    Cheng YS; Yu W; Xu Y; Salomon RG
    J Nat Prod; 2017 Feb; 80(2):488-498. PubMed ID: 28195470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Structures of Isolevuglandin-Protein Cross-Links.
    Bi W; Jang GF; Zhang L; Crabb JW; Laird J; Linetsky M; Salomon RG
    Chem Res Toxicol; 2016 Oct; 29(10):1628-1640. PubMed ID: 27599534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts.
    Guo L; Chen Z; Amarnath V; Yancey PG; Van Lenten BJ; Savage JR; Fazio S; Linton MF; Davies SS
    Antioxid Redox Signal; 2015 Jun; 22(18):1633-45. PubMed ID: 25751734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolevuglandin adducts in disease.
    Salomon RG; Bi W
    Antioxid Redox Signal; 2015 Jun; 22(18):1703-18. PubMed ID: 25557218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells.
    Sidorova TN; Yermalitskaya LV; Mace LC; Wells KS; Boutaud O; Prinsen JK; Davies SS; Roberts LJ; Dikalov SI; Glabe CG; Amarnath V; Barnett JV; Murray KT
    J Mol Cell Cardiol; 2015 Feb; 79():295-302. PubMed ID: 25463275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometry detection of isolevuglandin adduction to specific protein residues.
    Charvet CD; Pikuleva IA
    Methods Mol Biol; 2015; 1208():285-98. PubMed ID: 25323515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinal and nonocular abnormalities in Cyp27a1(-/-)Cyp46a1(-/-) mice with dysfunctional metabolism of cholesterol.
    Saadane A; Mast N; Charvet CD; Omarova S; Zheng W; Huang SS; Kern TS; Peachey NS; Pikuleva IA
    Am J Pathol; 2014 Sep; 184(9):2403-19. PubMed ID: 25065682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with pyridoxamine mitigates isolevuglandin-associated retinal effects in mice exposed to bright light.
    Charvet CD; Saadane A; Wang M; Salomon RG; Brunengraber H; Turko IV; Pikuleva IA
    J Biol Chem; 2013 Oct; 288(41):29267-80. PubMed ID: 23970548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttranslational modification by an isolevuglandin diminishes activity of the mitochondrial cytochrome P450 27A1.
    Charvet CD; Laird J; Xu Y; Salomon RG; Pikuleva IA
    J Lipid Res; 2013 May; 54(5):1421-9. PubMed ID: 23479405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid mediators in plasma of autism spectrum disorders.
    El-Ansary A; Al-Ayadhi L
    Lipids Health Dis; 2012 Nov; 11():160. PubMed ID: 23170784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a human apolipoprotein a-I construct expressed in a bacterial system.
    Prieto ED; Ramella N; Cuellar LA; Tricerri MA; Garda HA
    Protein J; 2012 Dec; 31(8):681-8. PubMed ID: 22986928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of phospholipid oxidation products in atherosclerosis.
    Lee S; Birukov KG; Romanoski CE; Springstead JR; Lusis AJ; Berliner JA
    Circ Res; 2012 Aug; 111(6):778-99. PubMed ID: 22935534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel oxidized levuglandin D2 in marine red alga and mouse tissue.
    Kanai Y; Hiroki S; Koshino H; Konoki K; Cho Y; Cayme M; Fukuyo Y; Yotsu-Yamashita M
    J Lipid Res; 2011 Dec; 52(12):2245-2254. PubMed ID: 21893678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and detection of levuglandins and isolevuglandins in vitro and in vivo.
    Zhang M; Li W; Li T
    Molecules; 2011 Jun; 16(7):5333-48. PubMed ID: 21705973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A liquid chromatography-tandem mass spectrometry method for measurement of N-modified phosphatidylethanolamines.
    Guo L; Amarnath V; Davies SS
    Anal Biochem; 2010 Oct; 405(2):236-45. PubMed ID: 20599652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.